Work

Supplementary Figure S6 from Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure S6. Prognostic signatures derived from all NSCLC patients consistently perform better in RASwt than in RASmt patients in current studies where the number of RASmt patients is smaller compared to the number of RASwt patients (A-C). When balancing the number of RASwt and RASmt patients it is clear that different signatures are prognostic in these patient groups (D-F). A,D, Distribution of logged HR in all, only RASwt and only RASmt patients (combined permutations of 5 - 100 genes). B,E, Percentages of random signatures vs. logged p-values in all, only RASwt and only RASmt patients (combined permutations of 5 - 100 genes). C,F, Log-odds of p-value Wald test in RASmt vs. p-value in RASwt patient groups as a function of gene-set size.

DOI: 10.1158/1078-0432.22458117

Authors: Maud HW. Starmans, Melania Pintilie, Michelle Chan-Seng-Yue, Nathalie C. Moon, Syed Haider, Francis Nguyen, Suzanne K. Lau, Ni Liu, Arek Kasprzyk, Bradly G. Wouters, Sandy D. Der, Frances A. Shepherd, Igor Jurisica, Linda Z. Penn, Ming-Sound Tsao, Philippe Lambin, Paul C. Boutros

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361915882

Cites:

Cited by:

Related to: 10